Showing 2271-2280 of 5623 results for "".
- CORE Demonstrates Advanced 3D Printing for Ocular Research at ARVO 2023https://modernod.com/news/core-demonstrates-advanced-3d-printing-for-ocular-research-at-arvo-2023/2481539/Scientists from the Centre for Ocular Research & Education (CORE) plan to unveil multiple advancements in 3D printing during the ARVO 2023 Annual Meeting in New Orleans. These innovations may widespread applications, with the potential to accelerate dev
- Nova Eye Medical Announces US Market Clearance of the iTrack Advance Canaloplasty Devicehttps://modernod.com/news/nova-eye-medical-announces-us-market-clearance-of-the-itrack-advance-canaloplasty-device/2481530/Nova Eye Medical announced that it has been granted FDA 510(k) clearance for its new canaloplasty device, iTrack Advance. The iTrack Advance has been cleared for microcatheterization and viscodilation to reduce IOP in adult patients with prim
- Allegro Ophthalmics Receives Approval from FDA for Design of Phase 2b/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMDhttps://modernod.com/news/allegro-ophthalmics-receives-approval-from-fda-for-design-of-phase-2b3-clinical-trial-of-risuteganib-for-the-treatment-of-intermediate-dry-amd/2481527/Allegro Ophthalmics announced that the company has received agreement from the FDA under a Special Protocol Assessment (SPA) for the design of its phase 2b/3 clinical trial of risuteganib (Luminate) for the treatment of intermediate, dry age-related macular degeneration (AMD).
- Kala Receives FDA Fast Track Designation for Human MSC-S Therapy for Persistent Corneal Epithelial Defecthttps://modernod.com/news/kala-pharmaceuticals-receives-fda-fast-track-designation-for-kpi-012-a-human-msc-s-therapy-for-persistent-corneal-epithelial-defect/2481526/The FDA has granted Fast Track designation for Kala Pharmaceuticals' human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) for the treatment of persistent corneal epithelial defect (PCED). “There is a significant unmet need for patients suffering from PCED, whic
- Peeq Waiva Multipurpose Eyelid Cleansing Device Now Availablehttps://modernod.com/news/peeq-waiva-multipurpose-eyelid-cleansing-device-now-available/2481525/Peeq Pro has announced the launch of the Peeq Waiva, an at-home cleansing device designed for daily use to gently and effectively clean eyelids and the skin around the eyes. When used consistently as part of a patient's at-home eye cleansing routine, the device is designed
- Nidek Announces the Winners of the 3rd Annual Images of the Year Awardhttps://modernod.com/news/nidek-announces-the-winners-of-the-3rd-annual-images-of-the-year-award/2481521/Nidek has announced the winners of the 3rd Annual Images of the Year Award. While continuing the theme “invisible to visible,” this year’s contest highlighted how multiple imaging techniques of the Mirante Scanning Laser Ophthalmoscope (NIDEK) helps retina specialists visua
- Radius Announces Software Upgrade for Wearable Device for Perimetric Examinationshttps://modernod.com/news/radius-announces-perimeter-software-upgrade-for-wearable-device/2481518/Radius XR has launched its Radius 1.0 software release for perimetric examinations. Its interface is designed to assist eye care practices in delivering more comprehensive glaucoma management. Radius is a portable Vision Diagnostic and Patient Engagement system that combi
- Pixium Vision Announces FDA Breakthrough Device Designation for the Prima System in Dry AMDhttps://modernod.com/news/pixium-vision-announces-fda-breakthrough-device-designation-for-the-prima-system-in-dry-amd/2481505/The FDA has granted Breakthrough Device Designation to Pixium Vision's Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision implanted in human patients with atrophic dry age-related macular
- Théa Open Innovation and Galimedix Partner to Develop and Commercialize GAL-101 for Ophthalmic Indicationshttps://modernod.com/news/thea-open-innovation-and-galimedix-partner-to-develop-and-commercialize-gal-101-for-ophthalmic-indications/2481497/Théa Open Innovation and Galimedix Therapeutics announced that they have signed a licensing agreement in which Galimedix will grant Théa exclusive rights for the development and commercialization of GAL-101, Galimedix’s lead disease-modifying compound, for the topical and
- Survey: Employees Value Vision Care as Much as Dental, but Many are Leaving Benefits on the Tablehttps://modernod.com/news/survey-employees-value-vision-care-as-much-as-dental-but-many-are-leaving-benefits-on-the-table/2481495/A new survey conducted by The Harris Poll for XP Health finds that employees value vision care as much as dental, but many are confused about how to take advantage of it—even when they have vision benefits. According to the